வைராலஜி & மைகாலஜி
திறந்த அணுகல்

சுருக்கம்

Baltic Post-marketing Study of Pegilated Interferon α-2a 40 KD Efficacy and Safety in Patients with HBeAg–Positive and HBeAg– Negative Chronic Hepatitis B

Ludmila Viksna, Agita Jeruma, Gunta Sture, Baiba Rozentale, Andrejs Ivanovs, Jazeps Keiss and Valentina Sondore

Introduction: Pegilated interferon alpha-2a 40KD (Pegasys?) is registered in European Union, and is indicated for the treatment of HBeAg positive or HBeAg negative chronic hepatitis B in adult patients with compensated liver disease, evidence of viral replication and increased ALT. The aim of this study was to evaluate efficacy and safety of Pegasys? for Pegasys?